NFKB1 and AL amyloidosis: Recent reports also showed that Velcade (bortezomib), a drug approved by the Food and Drug Administration for the treatment of multiple myeloma, induces NF-κB, instead of inhibiting as was thought by inducing caspase-dependent mechanisms [38].